晚发,持久的自身免疫肝素诱导的血小板缺血与瘤在面外科手术后
Valerie J Will1, Tobias Tritschler2, Caterina E Marx2
1Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland valeriejasmina.will@insel.ch.
BMJ case reports
|February 15, 2026
概括
在手术后发生了一种罕见的延迟自身免疫肝素诱导血小板缩 (HIT) 病例. 及时识别和免疫球蛋白治疗导致了康复,强调了持续性血小板缺血时需要保持警的必要性.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 氨酸诱导的血小板缺血 (HIT) 是氨酸治疗的严重免疫中介并发症.
- 延迟发病和持续的自身免疫性HIT (aHIT) 是不太常见但关键的表现.
- 耐火性HIT的管理需要替代抗凝药和潜在的免疫调节疗法.
研究的目的:
- 报告一个独特的延迟发病的病例,在预防性未分离肝素 (UFH) 后持续的自身免疫性HIT (aHIT).
- 为突出诊断挑战和治疗策略的aHIT.
- 强调在患有持续性血小板缺血症的患者中识别和管理aHIT的重要性.
主要方法:
- 病例报告详细介绍了一名中脸部和下骨折手术的患者.
- 初始呈现与肺栓塞和轻度血小板缺血后UFH停止.
- 通过阳性HIT抗体免疫测试和功能测试 (HIPA) 证实了诊断,显示氨酸独立活性.
- 用阿格拉特罗班治疗,然后给予静脉注射免疫球蛋白 (IVIG).
主要成果:
- 患者出现了与HIT一致的严重血小板缩,尽管最初的抗凝药停止.
- 标准的HIT治疗有阿斯巴特罗班是无效的.
- 通过实验室检测证实了延迟发病,持续性HIT的诊断.
- 通过IVIG治疗导致血小板数的快速恢复.
结论:
- 延迟发作的,持续的自身免疫性HIT (aHIT) 即使在预防性UFH和药物停止后也可能发生.
- 功能性测试中的氨酸独立抗体活性支持aHIT诊断.
- 静脉注射免疫球蛋白 (IVIG) 可以成为耐火性心脏病的有效治疗方法.
- 早期识别和适当的治疗,包括考虑IVIG,对于患有持续性血小板缺血和疑似aHIT的患者至关重要.
相关概念视频
Venous Thrombosis III: Interprofessional Care
383
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
383
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K


